Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 1. EGFR-TK Inhibitors

Generic Name Trade Name [development name] FDA-approved Indications Dosage Mechanism of Action
Gefitinib Iressa™ [ZD1839] Advanced NSCLC 250-500 mg PO daily Inhibits the intracellular tyrosine kinase (TK) of epidermal growth factor receptor (EGFR), resulting in cell cycle arrest, apoptosis, and inhibition of angiogenesis and tumor cell invasion
Erlotinib Tarceva™ [OSI-774] NSCLC 150 mg PO daily
- - Not marketed [CI-1033] Not yet approved  
Lapatinib Not marketed [GW572016] Not yet approved  
- - Not marketed [EKB-569] Not yet approved  

Abbreviations: EGFR-TK = epidermal growth factor receptor tyrosine kinase; FDA = Food and Drug Administration; NSCLC = non-small cell lung cancer; PO = per os (by mouth).

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care